Aurinia PharmaceuticalsAUPH 
$9.55-0.83%24h
-0.83%24h
Global rank1982
Market cap$1.37B
Change 7d-8.96%
YTD Performance7.79%
SP500 benchmarkUnderperform
P/E-17.69
P/S7.79
Revenue$175.51M
Earnings-$78.02M
Dividend yield-
Main Sector
Healthcare
Category
Aurinia Pharmaceuticals (AUPH) Stock Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
AUPH Stock Information
Symbol
AUPHAddress
4464 Markham StreetVictoria, BC V8Z 7X8Canada
Founded
-Trading hours
-Website
https://www.auriniapharma.comCountry
🇨🇦 CanadaPhone Number
250 708 4272Aurinia Pharmaceuticals (AUPH) Price Chart
-
Value:-
Aurinia Pharmaceuticals Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $9.55 | N/A |
| Market Cap | $1.37B | N/A |
| Shares Outstanding | 143.24M | 0.93% |
| Employees | 300.00 | N/A |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -17.69 | N/A |
| P/S Ratio | 7.79 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $175.51M | N/A |
| Earnings | -$78.02M | N/A |
| EPS | -0.54 | N/A |
| Earnings Yield | -0.0565 | N/A |
| Gross Margin | 0.9194 | N/A |
| Operating Margin | -0.5224 | N/A |
| Net income margin | -0.4445 | N/A |
